Anti-Mouse CXCL9 (Clone MIG-2F5-5) – Purified in vivo PLATINUM™ Functional Grade

Mouse plasmacytoid dendritic cells

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM^TM antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

N IF

MIG-2F5-5 activity is directed against murine CXCL9 (monokine induced by gamma interferon, MIG).

CXCL9 is a chemokine, which are small 8-15 kDa proteins that function in immune responses¹. CXCL9, -10, -11 and their receptor CXCR3 regulate immune cell migration, differentiation, and activation, leading to tumor suppression in the paracrine axis. However, in the autocrine axis, they may be involved in tumor growth and metastasis. The CXCL9, -10, -11/CXCR3 axis also regulates differentiation of naïve T cells to T helper 1 (Th1) cells. CXCL9, -10, and -11 are usually expressed at low levels but are upregulated by cytokine stimulation. CXCL9 is dependent on IFNγ for expression². CXCL9 is also capable of direct antimicrobial activity against pathogen infection³. CXCL9 is secreted by macrophages⁴, monocytes, endothelial cells, fibroblasts, and cancer cells in response to IFN-γ¹ and is also expressed in intratumoral dendritic cells⁵. CXCL9 is also detectable in CD103⁺ conventional dendritic cells (cDCs) isolated from transgenic murine MMTV-PyMT tumors following in vivo administration of brefeldin A⁵. Additionally, CXCL9 is detectable in myeloid cells following ex vivo stimulation with IFN-γ. Furthermore, CXCL9 expression is enhanced in CD8α⁺ cDC1s when anti-TIM-3 is added. Neutralizing antibodies against Galectin-9 lead to an increase in CXCL9 expression comparable to that induced by anti-TIM-3 antibody. Additionally, endothelial cell expression of CXCL9 is strongly increased in liver sinusoidal endothelial cells isolated from nonalcoholic steatohepatitis mouse livers⁶. MIG-2F5-5 was generated by immunizing male Armenian hamsters with recombinant murine CXCL9, and specificity was confirmed by ELISA⁷.

CXCL9 is mainly secreted by macrophages, monocytes, endothelial cells, fibroblasts, and cancer cells in response to IFN-γ and is also expressed in intratumoral dendritic cells.

1. Tokunaga R, Zhang W, Naseem M, et al. Cancer Treat Rev. 63:40-47. 2018.
2. Cole KE, Strick CA, Paradis TJ, et al. J Exp Med. 187: 2009–2021. 1998.
3. Reid-Yu SA, Tuinema BR, Small CN, et al. PLoS Pathog. 11(2):e1004648. 2015.
4. Marcovecchio PM, Thomas G, Salek-Ardakani S. J Immunother Cancer. 9(2):e002045. 2021.
5. de Mingo Pulido Á, Gardner A, Hiebler S, et al. Cancer Cell. 33(1):60-74.e6. 2018.
6. Xiong X, Kuang H, Ansari S, et al. Mol Cell. 75(3):644-660.e5. 2019.
7. Krug A, Uppaluri R, Facchetti F, et al. J Immunol. 169(11):6079-6083. 2002.
8. Asai A, Tsuda Y, Kobayashi M, et al. Infect Immun. 78(10):4311-4319. 2010.